Monday, April 04, 2022 12:52:59 AM
Chuckles 759… My 2 Cents on Safety..!!!
A Clinical Trial Site has 24 hrs to report a SAE , that it becomes aware of… both to the Sponsor AND the IRB , overlooking the study.
Amarex May have been casual in it’s approach regarding Safety signals..!!!
However..!!!
The IRB’s overlooking our studies were the ones..EACH AND EVERY SAE..was reported to. These IRB’s are responsible to evaluate the causality determined by the investigator .. and determine whether the drug may continue to be administered to patients..!!!
Amarex has NOTHING to do with our Clinical Trial Investigators reporting SAE’s to the IRB..!!!
To assume ALL the investigators..ALL the IRB’s conducting CYDY sponsored studies..were incompetent..is a stretch..!!!
At the conclusion of each study..Amarex had to have EVERY Clinical Trial Site ..Close out EVERY SAE..that occurred at THEIR site.
The close out report by Amarex had to include every SAE ..reported during the study.
This report is sent to the overlooking IRB..Which independently verifies the SAE’s reported in the close out report by Amarex..With the SAE’s it independently received from the Clinical Trial Sites..!!!
The chances of rogue Physicians and IRB’s spread all across our country..Coming together just in CYDY trials..!!!
In small to NONE..!!!
IMHO.
A Clinical Trial Site has 24 hrs to report a SAE , that it becomes aware of… both to the Sponsor AND the IRB , overlooking the study.
Amarex May have been casual in it’s approach regarding Safety signals..!!!
However..!!!
The IRB’s overlooking our studies were the ones..EACH AND EVERY SAE..was reported to. These IRB’s are responsible to evaluate the causality determined by the investigator .. and determine whether the drug may continue to be administered to patients..!!!
Amarex has NOTHING to do with our Clinical Trial Investigators reporting SAE’s to the IRB..!!!
To assume ALL the investigators..ALL the IRB’s conducting CYDY sponsored studies..were incompetent..is a stretch..!!!
At the conclusion of each study..Amarex had to have EVERY Clinical Trial Site ..Close out EVERY SAE..that occurred at THEIR site.
The close out report by Amarex had to include every SAE ..reported during the study.
This report is sent to the overlooking IRB..Which independently verifies the SAE’s reported in the close out report by Amarex..With the SAE’s it independently received from the Clinical Trial Sites..!!!
The chances of rogue Physicians and IRB’s spread all across our country..Coming together just in CYDY trials..!!!
In small to NONE..!!!
IMHO.
Recent CYDY News
- CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/22/2026 12:30:00 PM
- CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study • GlobeNewswire Inc. • 04/21/2026 08:10:00 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/20/2026 12:30:00 PM
- CytoDyn to Present at the AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/14/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/08/2026 09:15:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/08/2026 12:30:28 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/25/2026 09:16:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:24:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:23:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:22:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:21:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 09:15:24 PM
- CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer • GlobeNewswire Inc. • 03/24/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/09/2026 09:15:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2026 01:35:02 PM
- CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab • GlobeNewswire Inc. • 03/05/2026 01:30:00 PM
- CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology Conference • GlobeNewswire Inc. • 02/20/2026 01:30:00 PM
- CytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast Cancer • GlobeNewswire Inc. • 01/27/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/09/2026 10:15:22 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 01/09/2026 01:30:45 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/22/2025 10:15:23 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 12/17/2025 05:15:14 AM
- December 2025 Letter to Shareholders • GlobeNewswire Inc. • 12/16/2025 01:30:00 PM
